Clinical Trials Logo

Gut Microbiome clinical trials

View clinical trials related to Gut Microbiome.

Filter by:

NCT ID: NCT06130137 Not yet recruiting - Chronic Hepatitis b Clinical Trials

Gut Microbiome in People Living With HIV and HBV

Start date: November 27, 2023
Phase:
Study type: Observational

Building a Microbiome Data Platform and Conducting Clinical Evidence Research in Individuals Infected with the Human Immunodeficiency Virus (HIV) and Hepatitis B virus.

NCT ID: NCT06006416 Withdrawn - Gut Microbiome Clinical Trials

Effect of Fenugreek Fibre on Gut Microbiome

Start date: September 1, 2023
Phase: Phase 3
Study type: Interventional

A open label, self-controlled trial to evaluate the effect of Fenugreek Fibre (Trigonella foenum-graecum) on the gut microbiome in generally healthy adults aged 18-65 years old.

NCT ID: NCT05931471 Active, not recruiting - Gut Microbiome Clinical Trials

Yogurt and GI Health

Start date: September 19, 2023
Phase: N/A
Study type: Interventional

The purpose of this research is to assess mucosal immune function responses in the gastrointestinal (GI) tract to twice-daily yogurt consumption. Previous research has shown that dairy yogurt intake can benefit gastrointestinal health. The current study will determine whether a dietary intervention with dairy yogurt will improve mucosal immunity and the gut microbiome.

NCT ID: NCT05821010 Recruiting - Clinical trials for Non-Alcoholic Fatty Liver Disease

Synbiotics and Fecal Microbiota Transplantation to Treat Non-Alcoholic Steatohepatitis

SYNCH
Start date: March 17, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to investigate the therapeutic potential of A. soehngenii and pasteurized A. muciniphila combined with B. animalis subsp. lactis and fructo-oligosaccharides with and without conditioned vegan lyophilized fecal microbiota transplantation capsules to reduce NASH in patients with fibrotic NASH. The main questions to answer are: 1. Can NASH be treated by altering the gut microbiota using LFMT capsules? 2. Can NASH be treated using a syntrophic cocktail of synbiotics and will these strains strengthen the effect of FMT? 3. What are the underlying mechanism by which the aforementioned treatments attenuate NASH? Participants will be treated with FMT-capsules or placebo, and all participants will receive a cocktail of 3 strains of probiotics and one type of prebiotic.

NCT ID: NCT05793112 Recruiting - Infant Development Clinical Trials

INF108F in Infants With Food Protein Induced Proctocolitis

RESTORE
Start date: September 9, 2023
Phase: Phase 4
Study type: Interventional

Single-center, randomized, double-blind, placebo-controlled trail evaluating INF108F in breastfed infants with FPIAP

NCT ID: NCT05774704 Recruiting - Safety Clinical Trials

Curcumin and Retinal Study

Start date: August 21, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

To test how two weeks of curcumin supplementation would cross the blood brain barrier (BBB) and attach to amyloid beta proteins, to assess the feasibility (safety and bioavailability), and to explore the resulting abundance/composition of gut microbiota.

NCT ID: NCT05670288 Recruiting - Clinical trials for Spinal Cord Injuries

Impact of Gut Microbiome on Metabolic and Bowel Function During the First Year After Spinal Cord Injury

Start date: October 15, 2023
Phase:
Study type: Observational

The Investigators will recruit 50 participants with acute SCI (within 72 hours of injury) Fasting blood collection and bowel function survey will be conducted 4 times: at baseline [the time of first stool sample, within 72 hours of injury] and 1, 6, and 12 months after SCI. Stool will be collected for gut microbiome analysis 4 times

NCT ID: NCT05655910 Recruiting - Heart Failure Clinical Trials

Enhanced Nutritional Optimization in LVAD Trial

ENOL
Start date: September 22, 2022
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to assess whether a peri-operative intervention with nutritional immune modulating intervention (Ensure Surgery Immunonutrition shake) has beneficial effects on the complex interplay between gut microbiome, systemic inflammation and malnutrition that is commonly present in advanced heart failure and the adverse events associated with left ventricular assist device (LVAD) placement in hospitalized advanced heart failure patients awaiting LVAD implantation. The main questions it aims to answer are: - Will pre-surgical supplementation with Ensure Surgery affect gut microbial composition and levels of inflammation among heart failure patients undergoing LVAD implantation? - Will pre-surgical supplementation with Ensure Surgery affect post-surgical morbidity (e.g., infections, intensive care unit length of stay (LOS)) and mortality? Participants will be evaluated for malnutrition and will be given Ensure Surgery Immunonutrition shake to drink in the days preceding their LVAD surgery. Blood and stool samples will be collected at prespecified timepoints before and after surgery. Researchers will compare malnourished participants drinking Ensure Surgery 3/day with well-nourished participants randomized to drink either 1/day or 3/day to see if any of the above supplementation strategies change the gut microbial composition, levels of inflammation, and post-surgical morbidity and mortality.

NCT ID: NCT05646784 Recruiting - Mood Disorders Clinical Trials

Gut Microbiota in Mood Disorders in Lebanese Population

Start date: January 24, 2024
Phase: N/A
Study type: Interventional

This study aims to evaluate the pathophysiological aspects of the role of inflammation and gut microbiota in mood disorders, in particular in depression, and their therapeutic implications on a cohort of the Lebanese population. Specific objective: The evaluation of probiotic intake (CEREBIOME®, Lallemand Health Solutions Inc., Mirabel, Canada) on depressive patients and the inflammatory state. Evaluate the effect of oral intake of a probiotic agent, on clinical and plasma inflammatory markers, in a subgroup of target patients versus a subgroup treated with placebo, in combination with conventional treatment.

NCT ID: NCT05615961 Completed - Gut Microbiota Clinical Trials

Effect of Probiotics on Endurance Athletes' Microbiome at Rest and Post-race

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

This study is intended to investigate the use of probiotics (LAB4 probiotics, Cultech, Port Talbot, Wales, UK) and the effect this has on gastrointestinal symptoms experienced during elite long-distance triathlon (ironman) competition, as well as the composition of the gut bacteria in the athlete. Long-distance triathlon events frequently induce gastrointestinal discomfort due to the duration of the event (8-17 hours), the intensity of the exercise and the ingestion of large amounts of sugars throughout the event. Data will be collected from athletes participating at the Kona ironman World-championships. Participants will supplement with either probiotic tablet, or placebo (sugar-pill) for 4-weeks prior to competition. Athletes will be both male and female age-group athletes from any qualifying age category (age categories are as follows: 18-24; 25-29; 30-34; 35-39; 40-44; 45-49; 50-54; 55-59; 60-64; 65-69; 70-74; 75-79; 80-84). The main investigation of the study will be the occurence/frequency/severity of gastrointestinal symptoms during training and competition between groups.